Advances in hematology · 2025
Hyper-CVAD in Adults With Acute Lymphoblastic Leukemia in Ecuador: A Multicenter Retrospective Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sabando Brenner, Quinonez Jairo, Orquera Andrés, Navarrete Danilo, Ramírez Jhoanna, Sanchez Lorena, Chisesi Teodoro, Oliveros Jorge, Pacheco María A, Trujillo María C, Plaza Carlos, Loor Yaira
Аннотация
BACKGROUND: The Hyper-CVAD protocol is a chemotherapy regimen widely used in hematological malignancies. It is considered one of most promising remission-leading treatment option for adults with acute lymphoblastic leukemia (ALL).
OBJECTIVE: To determine the outcomes of adults with ALL treated with the Hyper-CVAD protocol in Ecuador.
METHODS: This multicenter, retrospective, cross-sectional study compared the outcomes of ALL patients aged 15 years and older treated with hyper-CVAD protocol in 8 specialized centers.
RESULTS: 139 patients with ALL treated with the Hyper-CVAD protocol were included. A total of 79 were female (56.8%) and the majority had a B-type phenotype 130 (93.5%). A complete response (CR) was achieved in 64.3%. Relapse was confirmed in 52.7% of those who obtained CR. Negative minimal residual disease (MRD) was achieved in 20% of patients. The median overall survival (OS) was 11 months (95% CI: 7.49-14.50) with a 5-year OS of 14.0%. A total of 12 (8.6%) deceased during induction phase.
CONCLUSION: Adult patients treated with the Hyper-CVAD protocol in Ecuador achieve rates of CR, MRD, and OS lower than those presented in international cohorts, as well as higher rates of treatment-related toxicity.
OBJECTIVE: To determine the outcomes of adults with ALL treated with the Hyper-CVAD protocol in Ecuador.
METHODS: This multicenter, retrospective, cross-sectional study compared the outcomes of ALL patients aged 15 years and older treated with hyper-CVAD protocol in 8 specialized centers.
RESULTS: 139 patients with ALL treated with the Hyper-CVAD protocol were included. A total of 79 were female (56.8%) and the majority had a B-type phenotype 130 (93.5%). A complete response (CR) was achieved in 64.3%. Relapse was confirmed in 52.7% of those who obtained CR. Negative minimal residual disease (MRD) was achieved in 20% of patients. The median overall survival (OS) was 11 months (95% CI: 7.49-14.50) with a 5-year OS of 14.0%. A total of 12 (8.6%) deceased during induction phase.
CONCLUSION: Adult patients treated with the Hyper-CVAD protocol in Ecuador achieve rates of CR, MRD, and OS lower than those presented in international cohorts, as well as higher rates of treatment-related toxicity.